Actively Recruiting
Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
Led by China National Center for Cardiovascular Diseases · Updated on 2024-08-30
66
Participants Needed
1
Research Sites
198 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.
CONDITIONS
Official Title
Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Clinically diagnosed hypertrophic cardiomyopathy with specific wall thickness criteria based on genetic status
- Non-obstructive left ventricular outflow tract with peak gradient less than 30 mmHg
- Persistent atrial fibrillation lasting more than 7 days but less than 3 years with drug-refractory symptoms
- Ability to understand the study and provide written informed consent
You will not qualify if you...
- Left atrial size greater than 60 mm by echocardiography
- Contraindication to systemic anticoagulation
- Left ventricular ejection fraction 40% or less
- Presence of left atrium or left atrial appendage emboli
- Coronary or valvular disease requiring intervention
- Ischemic stroke within the last 2 months
- Previous history of ablation for atrial fibrillation
- Uncontrolled hyperthyroidism or hypothyroidism
- End-stage kidney failure
- Participation in other clinical trials
- Pregnant or breastfeeding, or women of childbearing age not using reliable contraception
- Active infection or bacteremia
- Anatomical reasons making thoracoscopic surgery unsuitable (e.g., prior chest surgery or radiotherapy)
- Unwilling or unable to comply with study procedures and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Actively Recruiting
Research Team
Z
Zhe Zheng, MD.PhD
CONTACT
Y
Yajie Tang, MD.PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here